INmune Bio (NASDAQ:INMB) Stock

INmune Bio

INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Elevate,Healthcare,With,Ai,Technology,Services.virtual,Health,Care,Analytics,Empower

Opinion

INMB

C-Suite Buy of the Week: Executive Moves from Biotech to Banking

doctor-3822863_1280

News

Movers & Shakers

ELAB

Elevai Labs, Inc. (NASDAQ:ELAB) shares are trading higher Tuesday after the company announced it signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio, Inc. (NASDAQ:INMB).

Why Elevai Labs Stock Is Trading Higher

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer’s Disease

Biotech

Interview

General

David Moss, CEO of INmune Bio (NASDAQ: INMB) was recently a guest on Benzinga’s All-Access.

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer&#39;s Disease

INmune Bio Inc

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy and raises the price target from $22 to $30.

Price Target

Analyst Ratings

Maxim Group Maintains Buy on INmune Bio, Raises Price Target to $30

WIIM

Inmune Bio shares are trading higher after the company announced the completion of the third and highest dose cohort of its Phase 1 portion of the INKmune trial in prostate cancer.

INmune Bio  Completes Third And Highest Dose Cohort Of Phase 1 Portion Of INKmune Trial In Prostate Cancer

Scotiabank analyst George Farmer maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Sector Outperform and raises the price target from $22 to $23.

Scotiabank Maintains Sector Outperform on INmune Bio, Raises Price Target to $23

Health Care

Following A Type C Meeting With FDA, INmune Bio Intends To Submit Us And European Marketing Applications Supported By Data From MissionEB Trial Of CORDStrom For Recessive Dystrophic Epidermolysis Bullosa In Pediatric Patients

INmune Bio Plans To Submit FDA Biologics License Application Seeking Approval Of CORDStrom For Recessive Dystrophic Epidermolysis Bullosa

INmune Bio Expands INKmune Trial In Prostate Cancer To Veterans

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$35.5K</td>
<td>6.0K</td>
<td>2.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$150.00</td>
<td>$66.4K</td>
<td>7.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$42.0K</td>
<td>3.0K</td>
<td>1.2K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$27.50</td>
<td>$109.6K</td>
<td>31.8K</td>
<td>1.1K</td>
</tr>
<tr>
<td>INMB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.00</td>
<td>$25.5K</td>
<td>2.1K</td>
<td>486</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$590.00</td>
<td>$45.0K</td>
<td>291</td>
<td>275</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>567</td>
<td>261</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$25.4K</td>
<td>511</td>
<td>220</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$62.50</td>
<td>$44.9K</td>
<td>137</td>
<td>189</td>
</tr>
<tr>
<td>BAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$35.00</td>
<td>$36.8K</td>
<td>68</td>
<td>160</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with bearish sentiment. It expires in 354 day(s) on January 16, 2026. Parties traded 163 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $35.5K, with a price of $218.0 per contract. There were 6058 open contracts at this strike prior to today, and today 2167 contract(s) were bought and sold. 
• For JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we notice a call option sweep that happens to be bearish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $150.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.4K, with a price of $336.0 per contract. There were 7225 open contracts at this strike prior to today, and today 1758 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a put option trade with bearish sentiment. It expires in 25 day(s) on February 21, 2025. Parties traded 200 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $42.0K, with a price of $210.0 per contract. There were 3069 open contracts at this strike prior to today, and today 1262 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bearish, expiring in 354 day(s) on January 16, 2026. This event was a transfer of 522 contract(s) at a $27.50 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $109.6K, with a price of $210.0 per contract. There were 31825 open contracts at this strike prior to today, and today 1191 contract(s) were bought and sold. 
• For INMB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>), we notice a call option sweep that happens to be bullish, expiring in 235 day(s) on September 19, 2025. This event was a transfer of 75 contract(s) at a $10.00 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $25.5K, with a price of $340.0 per contract. There were 2116 open contracts at this strike prior to today, and today 486 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on January 31, 2025. Parties traded 200 contract(s) at a $590.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $45.0K, with a price of $225.0 per contract. There were 291 open contracts at this strike prior to today, and today 275 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option sweep that happens to be bullish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 252 contract(s) at a $30.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $135.0 per contract. There were 567 open contracts at this strike prior to today, and today 261 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option trade that happens to be bearish, expiring in 25 day(s) on February 21, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $510.0 per contract. There were 511 open contracts at this strike prior to today, and today 220 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 53 day(s) on March 21, 2025. This event was a transfer of 156 contract(s) at a $62.50 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.9K, with a price of $288.0 per contract. There were 137 open contracts at this strike prior to today, and today 189 contract(s) were bought and sold. 
• For BAX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), we notice a call option trade that happens to be bullish, expiring in 718 day(s) on January 15, 2027. This event was a transfer of 80 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $36.8K, with a price of $460.0 per contract. There were 68 open contracts at this strike prior to today, and today 160 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ISRG

SWTX

TEVA

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

It is all true.
The market is priced at ridiculous levels.
The current multiples of earnings, cash flow, assets, and dividends of the S&amp;P 500 (Ticker: SPY) imply that we live in a perfect world and perfection will continue to grow at a double-digit rate.
We do not live in a perfect world.
The bond market, usually the far brighter and less emotional market, has been showing great concern and a smudge of outright fear in recent weeks. It has reentered a downtrend even as stocks went higher.
Should we just sell and hide under a rock on top of a mountain somewhere until the headlines improve?
Probably not.
If we have learned nothing else, it is that markets can remain irrational, unrealistic, and overpriced for a very long time.
What we can do is become cautious.
Avoid companies where insiders are selling as the price declines.
Avoid stocks that are being sold by smart money investors with outstanding track records.
Flipping that over, if you are looking to put money to work, look for companies where insiders are making large open-market purchases of shares of the companies they manage.
Look for companies where investors with great track records are stepping up and establishing new company positions.
I recently sat down to review institutional buying and selling activity, and a couple of purchases caught my eye.
One such smart money buy was a biotech company.
Let me be upfront and say that I know nothing about biotechnology.
I am not a doctor, I have never played a doctor on television, and I generally avoid small-cap biotech stocks because that is where money goes to die.
There have been a handful of exceptions over the years, and they were all the result of noticing that a very smart, very successful investor had bought a lot of stock.
I noticed that Harris Kupperman of Praetorian Capital had purchased a 5.5% stake in Immune Bio (Ticker: INMB).
Kupperman, or JKuppy as he prefers to be called apparently, is not everyone&#8217;s cup of tea.
He can come across as brash, opinionated, and a tad arrogant.
He runs part of his fund in deep-value stocks and the other half in special situations.
It is almost like looking in a personality mirror.
He is also very good at what he does.
Kupperman runs his fund to do okay in what he calls standard years and to really push the edge when he feels he has uncovered opportunities in deeply undervalued markets and sectors.
It is working.
Since 2019, his fund is up a little over 700%.
Immune Bio is working on developing drugs using its core research that could help treat depression and Alzheimer&#8217;s.
Both are massive markets that could lead to substantial partnership opportunities or licensing deals for a company that progresses in developing a successful drug.
The folks at Praetorian are not the only ones excited about the stock. Raymond James analyst Gary Nachman recently wrote a favorable report with an $18 price target for shares of Immune Bio.
That is almost three times the current stock price.
The true test of another intelligence is how much they agree with me, and a closer peek into Praetorian&#8217;s portfolio at the end of the third quarter shows that he bought shares of one of my favorite Japanese firms, Nomura (Ticker: NMR).
Nomura has had one of those years that just naturally attracts my attention.
One staffer tried to manipulate the bond market, and the firm had to pay a fine and temporarily lost its status as a primary dealer.
Then, a Nomura staffer was arrested for attempting to murder an elderly client.
These are not the kind of headlines that attract enthusiastic buyers of your stock.
None of this impacts a firm of Nomura&#8217;s size, but it creates a cloud around the stock that creates buying opportunities.
The scandals have partially masked that business at Nomura is pretty good. Revenues are rising, and profits more than doubled, as the company reported its largest profits in four years.
The company is buying back stock and paying a cash dividend of 4.3%, rewarding shareholders with its excess cash.
The company is increasing its presence outside of Asia, focusing on wealthy markets like the Americas, India and the Middle East. Early results are promising, with solid gains in the number of customers for both wealth management and investment banking in these markets.
In spite of the strong results and positive outlook, the stock is trading at just 82% of tangible book value and less than ten times earnings.
These are uncertain times in financial markets.
There are as many possible outcomes as there are questions about what lies ahead in 2025.
Avoiding stocks where insiders and the smart money are selling and accumulating the ones they are buying can help us navigate turbulent waters profitably.

Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes

OmniScience And INmune Bio Partner To Accelerate Phase 2 Alzheimer's Trial With Vivo

INmune Bio Completed Randomization Of Patients For Its Phase 2 Trial

INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.50) by 20 percent. This is a 25 percent decrease over losses of $(0.48) per share from the same period last year.

Earnings

Earnings Misses

INmune Bio Q3 EPS $(0.60) Misses $(0.50) Estimate

INmune Bio shares are trading higher after the company announced it will host a webinar on cognitive testing using EMACC and CDR-SB on November 7 at 1 pm ET.

"Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials" Webinar to be Held on November 7, 2024, at 1 PM ET.
Poster on EMACC Sensitivity and Performance in Phase II Alzheimer's Trial to be Presented at CTAD2024
Boca Raton, Florida, Oct. 28, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=6s8KWaUzAwqubvNXKfWRdgyHHbqBhVyfHJuyW2HkHSNoFa2__Lm6gWqUINuxzs0KK6qhQzBtvLHEcHq0vp1iO8QYJzIbce0azdw7XTvSh0EBwPYhbfQrIR_r9wSdWmsVGCVG-V7FrekEFnohTpCzOkrtbKbg9f_0tvreLsuK8LZfFQtPccUeGW4GfP2VImcfDt-eFV0sABvddjYTuYBz6Go9R7hmD-_na6mBStMbeBGsVVR46Z5tNyPOk5ypMw3tcZeCkKrA6Kr7QS6zONKwSSdfIJiIo17LdwuIvEtVeHj6389KI4mQ3AvW7hN3OFmpa5yF1U3T1NGuD_EyrDEnB2Nc9tTsSyOrlHpRVhyX-tK22-xBxHcXJxjEBzpEGfObOaBdUnnn6YEbFsPZz4DBCBmHnZUbSJhhA60Y-YG61ZqTcqi8baXLoedBKNAQ0ExAz-_Hf1r_Qq4A97ovJVHIKA==">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease is hosting a Webinar on November 7, 2024 at 1 PM ET.
The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials," will explore the development of EMACC and its advantages in assessing cognitive changes over time in early Alzheimer's Disease (AD) patients. It will also cover the regulatory landscape for Alzheimer's disease drug development and the role of the CDR-SB clinical scale. Speakers include Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, Dr. Sarah Barnum, and CJ Barnum, VP of CNS Drug Development at INmune Bio.

INmune Bio Inc. To Host Webinar On Cognitive Testing Using EMACC And CDR-SB On November 7, 2024, At 1 PM ET

Data from Animal Model Study Demonstrate XPro&#x2122; converts microglia from a demyelinating cell to a remyelinating cell &nbsp;
Multi-year study published has implications for many CNS diseases including Alzheimer's
Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=7tPZlwv14diVgOj9zG2t9UjV6ed0y__rf2yOtS4-8WgTVbHzna772LgK5h1hUWFNmPJqpjI6DNnNhcbkAcfvKWUppwKIenbogc-v_UsvWa4=">INmune Bio, Inc.</a>&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announces the publication of a seminal paper in the journal Cell Reports that demonstrates XPro1595 promotes remyelination in an animal model of demyelinating disease. The study, <a href="https://www.globenewswire.com/Tracker?data=Y256I8uMswP5hrKqLX5SJfQyiGYsFtnr7mmHRU10GuUytoNjX1jBIFQCoe0NW4KVtpTJ_dmm-iRjwiRtsIKetlOk3hBzuFs2LVG9dnVJK6JRPShLBU0a7uclGufquuie0njmAsvcXuj12EakN82oZui7WnWHKgeh18hWOrI1NoH6BnwLOaTUPfvyGtDd2YPWAxwsiKJksUGytS4SuUhM04qFBCKJaT67AFGAUU7z85E-7q3knP4t9jnOiegOc18rCXi76Q8bdGrif-FbHs5KhvqPn2_9o2aa9W8rvw8YeGU=">Microglia Regulate Cortical Remyelination via ΤNFR1-Dependent Phenotypic Polarization</a>, was performed under the direction of Leslie Probert PhD, Head of Immunology at the Hellenic Pasteur Institute in Athens Greece, and is the culmination of several years of work supported by EU research grants.
Myelin is necessary for fast and efficient communication between neurons. Loss of myelin compromises neuron function and communication and is a key step in the neurodegenerative process of many CNS diseases, including Alzheimer's Disease.

INmune Bio Announces Publication In Cell Reports That Demonstrates XPro1595 Promotes Remyelination In An Animal Model Of Demyelinating Disease

Alliance Global Partners analyst James Molloy initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy rating and announces Price Target of $20.

Initiation

Alliance Global Partners Initiates Coverage On INmune Bio with Buy Rating, Announces Price Target of $20

INmune Bio Inc. Completes Enrollment For Phase 2 Trial In Early Alzheimer's Disease

Raymond James initiates coverage on INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Outperform rating and announces Price Target of $18.

Raymond James Initiates Coverage On INmune Bio with Outperform Rating, Announces Price Target of $18

INmune Bio shares are trading higher after the company announced its INKmune Phase I/II trial for metastatic castration-resistant prostate cancer (mCRPC) demonstrated excellent safety and increased NK-cell activity in the first dosing cohort.

INmune Bio's INKmune Demonstrates Excellent Safety And Increased NK-Cell Activity In First Dosing Cohort Of Phase I/II Trial For Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Press Releases

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

INmune Bio

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga